GH250516C43000
- 5.30
- 0.000.00%
Guardant Health Newsroom
CCORF Maintains Guardant Health(GH.US) With Buy Rating
Guardant Health's Strategic Advancements in Multi-Cancer Detection Reinforce Buy Rating
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $60
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $60
BofA Securities Raises Price Target on Guardant Health to $60 From $56, Keeps Buy Rating
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $55
Guardant Health Is Maintained at Overweight by Barclays
Barclays Maintains Overweight on Guardant Health, Lowers Price Target to $55
Guardant Health Price Target Announced at $55.00/Share by Mizuho
Guardant Health Initiated at Outperform by Mizuho
Guardant Health Analyst Ratings
Mizuho Securities Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $55
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Guardant Health Price Target Maintained With a $55.00/Share by Stephens & Co.
Guardant Health Analyst Ratings
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $60
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating, Announces Target Price $56
BTIG Keeps Their Buy Rating on Guardant Health (GH)
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $56 to $60
Guardant Health (GH) Receives a Buy From Barclays